Literature DB >> 7636051

Inhibition of monocyte leukotriene B4 production after aspirin desensitization.

U R Juergens1, S C Christiansen, D D Stevenson, B L Zuraw.   

Abstract

Aspirin-sensitive patients may be desensitized through a graded series of exposures to aspirin. We investigated the underlying mechanism of aspirin desensitization by measuring the release of leukotrienes B4 and C4 from calcium ionophore-stimulated peripheral blood monocytes. Compared with monocytes from normal volunteers (n = 5), monocytes from patients with aspirin-sensitive asthma (n = 10) released increased amounts of thromboxane B2 (1060 +/- 245 pg/ml vs 456 +/- 62 pg/ml), leukotriene B4 (861 +/- 139 pg/ml vs 341 +/- 44 pg/ml), and leukotriene C4 (147 +/- 31 pg/ml vs 56 +/- 6 pg/ml) at baseline. After aspirin desensitization, thromboxane B2 release was almost completely suppressed in both groups. Leukotriene B4 release was significantly decreased in the aspirin-sensitive group (484 +/- 85 pg/ml) but not in the normal subject group (466 +/- 55 pg/ml). The need for prednisone decreased significantly after patients were desensitized to aspirin (10.4 +/- 2.2 mg/day to 1.6 +/- 2.8 mg/day). These results demonstrate that desensitization to aspirin results in decreased monocyte leukotriene B4 release. On the basis of the bronchospastic and inflammatory potential of leukotrienes, the decrease in leukotriene release may contribute to the clinical improvement seen after aspirin desensitization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636051     DOI: 10.1016/s0091-6749(95)70002-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  16 in total

1.  [Adaptive desensitization for acetylsalicylic acid hypersensitivity: A success story?].

Authors:  G Mühlmeier; R Hausch; H Maier
Journal:  HNO       Date:  2015-10       Impact factor: 1.284

Review 2.  Pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  Donald D Stevenson; Bruce L Zuraw
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 3.  Factors driving the aspirin exacerbated respiratory disease phenotype.

Authors:  John W Steinke; Larry Borish
Journal:  Am J Rhinol Allergy       Date:  2015 Jan-Feb       Impact factor: 2.467

Review 4.  Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future.

Authors:  Joshua L Kennedy; Ashley N Stoner; Larry Borish
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

5.  Immunomodulatory treatments for aspirin exacerbated respiratory disease.

Authors:  Rachel G Moebus; Joseph K Han
Journal:  Am J Rhinol Allergy       Date:  2012 Mar-Apr       Impact factor: 2.467

Review 6.  Aspirin-induced asthma: clinical aspects, pathogenesis and management.

Authors:  Ahmed M Hamad; Amy M Sutcliffe; Alan J Knox
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs).

Authors:  Ronald A Simon; Jennifer Namazy
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

8.  Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease.

Authors:  Ayse Aktas; Emel Kurt; Zafer Gulbas
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

9.  Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.

Authors:  Elina Jerschow; Zhen Ren; Golda Hudes; Marek Sanak; Esperanza Morales; Victor Schuster; Simon D Spivack; David Rosenstreich
Journal:  Ann Allergy Asthma Immunol       Date:  2016-01-25       Impact factor: 6.347

Review 10.  Update on recent advances in the management of aspirin exacerbated respiratory disease.

Authors:  Nami Shrestha Palikhe; Joo-Hee Kim; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.